Spatial and temporal distribution of the prevalence of unemployment and early retirement in people with multiple sclerosis: A systematic review with meta-analysis

Bruno Kusznir Vitturi1*, Alborz Rahmani1,2, Guglielmo Dini1,2, Alfredo Montecucco1,2, Nicoletta Debarbieri1, Paolo Bandiera3, Mario Alberto Battaglia4,5, Tommaso Manacorda4, Benedetta Persechino6, Giuliana Buresti6, Michela Ponzio4, Matilde Inglese7,8, Paolo Durando1,2

1 Department of Health Sciences, University of Genoa, Genoa, Italy, 2 IRCCS Ospedale Policlinico San Martino, Occupational Medicine Unit, Genoa, Italy, 3 Italian Multiple Sclerosis Association (AISM), Genoa, Italy, 4 Scientific Research Area, Italian Multiple Sclerosis Foundation (FISM), Genoa, Italy, 5 Department of Life Science, University of Siena, Siena, Italy, 6 Italian Workers’ Compensation Authority (INAIL), Genoa, Italy, 7 Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI) and Center of Excellence for Biomedical Research (CEBR), University of Genoa, Genoa, Italy, 8 IRCCS Ospedale Policlinico San Martino, Genoa, Italy

* bruno.kusznir.vitturi@edu.unige.it

Abstract

Background
We aimed to summarise the prevalence of unemployment and early retirement among people with MS and analyze data according to a spatio-temporal perspective.

Methods
We undertook a systematic search of PubMed/MEDLINE, Scopus, SciVerse ScienceDirect, and Web of Science. We included any peer-reviewed original article reporting the prevalence of unemployment and early retirement in the working-age population with MS. We excluded articles off-topic, with other study designs, whose study sample were unlikely to be representative of the MS population and in case of unavailability of the full text or essential information. A random-effects meta-analysis was used to measure overall prevalence estimates of unemployment and early retirement. We used meta-regression and subgroup analysis to evaluate potential moderators of prevalence estimates and the leave-one-out method for sensitivity analyses.

Results
Our research identified 153 studies across 29 countries encompassing 188436 subjects with MS. The pooled overall effect size for unemployment and early retirement was 35.6% (95% CI 32.8–38.4; I² = 99.31) and 17.2% (95% CI 14.6–20.2; I² = 99.13), respectively. The prevalence of unemployment varied according to the year of publication (p < 0.001) and there was a statistically significant decrease in the prevalence of unemployment over time.
Regarding early retirement, only seven (31.8%) estimates obtained from studies that were published before 2010 were below the overall effect size in comparison to 27 (60.0%) estimates extracted from data published between 2010 and 2021 (p = 0.039). There was a significant difference in prevalence according to countries (p < 0.001). Psychiatric illness was an important clinical feature responsible for patients leaving the workforce in regions with a high MS prevalence.

**Conclusions**

Unemployment and early retirement due to MS remain highly prevalent, despite a slight decline in the last decade. The prevalence of unemployment and early retirement varies globally.

**Introduction**

Multiple Sclerosis (MS) is a chronic autoimmune disease that causes demyelination and neurodegeneration in the central nervous system. It mainly affects young people between 20 and 40 years of age and it is the main cause of non-traumatic disability among young adults in the Western world [1]. About 2.8 million people worldwide suffer from MS, whose incidence and prevalence increase in both developed and developing countries [2]. The symptoms are extremely varied and the clinical course is within a spectrum that extends from relapsing-remitting to progressive [3].

Besides the inherent clinical complexity of MS, the age of onset of the disease brings inevitable repercussions to work activity, once it coincides with the moment in which people with MS (PwMS) find themselves managing the already expected difficulties of the job market and the beginning of the professional career [4, 5]. Often limiting and disabling, symptoms such as fatigue, neuropsychiatric impairment, and motor disturbances constantly threaten the full performance at work and the search for new professional skills [6, 7]. PwMS are vulnerable to barriers related to the work environment (e.g. high temperature level, difficult access to the workplace, noise) deterioration of social relationships at work, negative work events and stigma and discrimination in the workplace. Moreover, intrinsic characteristics of the job such as inflexible work schedules and extended standing time can make work unviable for PwMS [8–10].

MS is recognized as a well-known risk factor for unemployment and early retirement. A Norwegian study found that after 19 years of disease, only 45% of patients were still employed [11]. In a Swedish cohort, only 28% and 23% of PwMS were working full- and part-time after a follow-up of ten years, respectively [12]. In 2013, Krause et al. showed that 44.8% of PwMS were forced to retire early due to their illness [13]. Once unemployed, PwMS face substantial difficulties to return to the workforce [14]. In addition to the undeniable importance that work plays in people’s lives and the financial and psychological consequences that the loss of a job can entail, unemployed and early retired patients are known to be associated with a worse level of quality of life [15].

Although unemployment and early retirement are already sufficiently eloquent consequences in the personal life of PwMS, it is impossible not to recognize the economic burden closely associated with these two outcomes. In Germany, approximately 27,300 persons received early retirement pensions caused by MS [16]. Battaglia et al. showed that invalidity
and early retirement can cost more than 18,000 € per patient every year [17]. Indeed, it is not frivolous to affirm that MS is one of the most costly diseases, once it dialogues with the global economy and the public health closely [18].

If, on the one hand, the literature is relatively abundant concerning data on unemployment and early retirement in MS, on the other hand, there is an enormous diversity of data that prevents clinicians and researchers from having the real dimension of this issue. In fact, there is no study aimed at systematically synthesising the available data. Over time, there have been remarkable advances in the understanding of MS and its treatment and, since 2010, several disease-modifying drugs (DMDs) have been approved [19]. Nevertheless, there is still no evidence indicating the temporal evolution of the occupational outcomes in PwMS. Moreover, there is also a complete lack of studies describing and comparing the prevalence of unemployment and early retirement considering a geographical point of view. Strategies to prevent these outcomes are complex and can vary substantially across countries. An accurate understanding of the geographical particularities of unemployment and early retirement is crucial to guide effective strategies to promote the integration of PwMS into work.

The influence of MS on unemployment and early retirement is a public health issue. In almost 40 years of published data on the prevalence of unemployment and early retirement in workers with MS, it is imperative to understand the full epidemiological and occupational context of the disease. Effective public health strategies depend on this type of approach and are crucial to promote the occupational outcomes and the quality of life of PwMS. Aware of this scenario and the importance of this topic, we performed the first systematic review with meta-analysis that address the prevalence of unemployment and early retirement in a temporal-spatial perspective. The review aimed to summarize the prevalence of unemployment and early retirement among PwMS, describe if there has been any significant change over time, and compare these two outcomes from a geographical point of view.

Materials and methods

This study was carried out according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement (PRISMA) [20] (S1 File) and the Joanna Briggs recommendations for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data [21]. The protocol was registered in PROSPERO (CRD42021285216). As this was a literature review, ethical approval wasn’t necessary as it didn’t involve the recruitment of subjects and data were analyzed from already published original articles.

Search strategy and selection criteria

From August 1, 2021, to October 30, 2021, we systematically searched on PubMed/MEDLINE, Scopus, SciVerse ScienceDirect, and Web of Science the following keywords (Employ OR unemploy OR occupation OR “work” OR vocation OR “work resumption” OR workplace OR “return to work” OR “workforce” OR “labour force” OR “labor force” OR Career OR Job OR “job retention” OR retire OR “disability pension” OR “work” OR “fitness for work”) AND (“Multiple sclerosis” OR “Disseminated Sclerosis” OR “Demyelinating Autoimmune Diseases” OR “Demyelinating Autoimmune Disorders” OR “Clinically Isolated Syndrome” OR “Demyelinating”). The details of the search strategy used are reported in S1 Fig. We didn’t explore any grey literature sources. We adopted a broad search methodology to ensure the maximum inclusion of studies reporting both outcomes. Articles were selected according to the CoCoPop (Condition/Context/Population) strategy. We included any peer-reviewed original article reporting the prevalence of unemployment
and early retirement of PwMS in the working age. MS must have been diagnosed according to accepted international criteria at the time of the study and/or confirmed by a doctor. No time limits were set for the search. We included articles whose full text was published in English, Italian, Spanish, French, and Portuguese. As this is a systematic review of epidemiological articles, studies should contain a minimum sample of 124 subjects. This number was calculated according to the formula $n = \frac{Z^2 \cdot p(1-p)}{d^2}$, where $n$ is the sample size, $Z$ is the $Z$ statistic for a given level of confidence (1.96), $p$ is the expected global prevalence, and $d$ is the precision (in a proportion of one; if 5%, $d = 0.05$). Data were taken from cross-sectional cohort studies and baseline measurements in longitudinal and interventional studies with clinical follow-up.

After we removed duplicate entries, we performed an initial screen of titles or abstracts to assess potential relevance and remove those off-topic. Screening of titles, abstracts, and full texts for each article was conducted by three experienced and trained investigators (BKV, AR, and AM), each blinded to the other’s ratings. In case of discrepancy, a final decision was made by a consensus. Afterward, we obtained relevant full-text articles, revaluated their eligibility, and determined their final inclusion or exclusion.

Studies written in languages other than the five pre-specified above and studies designed as reviews, letters to the editor, expert opinions, commentaries, case reports, case series, editorials were excluded. In case of articles with missing or dubious data or without an available full text, we tried to contact the corresponding author twice to obtain more information by email. The study was excluded whenever our contact attempt failed. We didn’t accept studies whose sample deliberately included patients with more than a chronic disease or in which MS was not the primary condition. When multiple articles reported data from the same population, the article with the highest number of variables described was selected. We also excluded studies whose study sample were unlikely to be representative of the total population with MS—for example, studies that only focus on specific MS phenotype, only included PwMS with specific deficits or comorbidities, studies that excluded subjects with any disability, or populations primarily selected by the variables of interest. Fig 1 provides the PRISMA flowchart overview of the search and screening strategy performed. Articles were exported and managed in Mendeley 1.19.8 (Elsevier, New York, USA).

**Data analysis and quality assessment**

Data extraction was done by two independent reviewers (BKV and AR) and eventual disagreements were resolved by discussion until a consensus was reached. From each eligible study, we extracted the prevalence of unemployment and early retirement. In the cases in which the proportion was not explicit, we calculated it using as the denominator the entire population of the study and as the numerator, the raw explicit number of subjects with any of the outcomes studied. In addition to the outcomes of interest, the following variables were extracted in a Microsoft Excel spreadsheet: name of the first author, year of publication, country, sample size, average age, gender, higher educational attainment (defined as > 12 schooling years), study design, mean Expanded Disability Status Scale (EDSS), mean disease duration, use of disease-modifying drugs (DMDs), MS phenotype (progressive or relapsing-remitting), the prevalence of fatigue, neuropsychiatric symptoms and cognitive impairment. Countries were grouped into continents and were classified by income according to the World Bank country classification 2021 [22]. A data extraction form was used to extract equivalent information in a standardized manner, and to also minimize the intra-examiner variability, all the extracted data were double-checked. Categorical variables are reported as prevalence (%) while numerical variables are reported as means with the respective standard deviation (SD).
Quality assessment of the included studies was carried out using JBI Critical Appraisal Checklist for Studies Reporting Prevalence Data [23]. This checklist was developed to determine the extent to which a prevalence study has addressed the possibility of bias in its design, conduct, and analysis. This questionnaire contains ten closed-ended questions related to the methodological quality of the study. Answers can be "Yes", "No", "Unclear", or "Not/Applicable". The higher the number of "Yes" answers, the higher the quality of the study.

Fig 1. PRISMA flowchart.
https://doi.org/10.1371/journal.pone.0272156.g001
We undertook an initial descriptive analysis of the studies. We used the random-effects model based on the binomial distribution to calculate the pooled estimates of the prevalence of unemployment and early retirement. Specifically, we explored the relationship between these two outcomes with time and geographic variability. When multiple estimates existed for a country and a publication year, these estimates were combined with a random-effects meta-analysis to provide a single estimate for that country or year. We did not use any special statistical treatment for analysing data coming from the same country over time. When at least ten studies presented a specific covariate, we performed a weighted meta-regression with a random-effects model to assess the effect of moderators on the pooled effect size. Differences between the effect sizes of categorical variables were assessed with the ANOVA Q-Test. Random-effects with separate estimates of $I^2$. Effect sizes were reported as proportions. We performed a subgroup analysis by year/time, country, continent, income-based country classification, younger age (< 50 years old), absence of vocational or higher education, disease duration of more than ten years, EDSS greater than 3.0, countries and continents with the highest prevalence of MS (> 200 people with MS per 100,000) [24]. We also did a sensitivity analysis to test the robustness of our findings and we removed possible outliers and studies with a high risk of bias to explore the influence of individual studies on the main results.

Statistical heterogeneity was assessed using the $I^2$ statistic and visually inspecting the forest plot. $I^2$ more than 75% was regarded as substantial heterogeneity [25]. We investigated the existence of publication bias using Egger’s linear regression test [26], Duval and Tweedie’s Trim and Fill analysis [27], and with the visual inspection of the funnel plots. A $p < 0.05$ was considered statistically significant. All statistical analyses were performed using ProMeta (version 3.0) and SPSS (version 28.0.1).

Results

We identified 104228 potentially eligible studies from the systematic search. Removing duplicates and screening the abstracts resulted in 1136 articles whose full-texts were assessed for eligibility. After applying all the inclusion and exclusion criteria, 152 articles were finally considered relevant and included in the qualitative and quantitative analysis (Fig 1). Overall, the total sample size comprised 188436 individuals with MS. The mean age ranged from 32.0 to 60.0 years, the female gender proportion ranged from 33.1 to 100.0%, and the prevalence of individuals with higher educational attainment varied from 24.0% to 88.0%. Concerning the disease characteristics, the mean EDSS and the mean disease duration ranged from 1.3 to 5.5 and 3.2 to 23.6 years, respectively. The proportion of subjects with progressive phenotype of MS varied from 4.6% to 100.0% and the prevalence of fatigue, neuropsychiatric symptoms and cognitive impairment ranged from 56.0% to 96.3%, 25.6% to 89.9%, and 48.1%–97.0%, respectively. Regarding the use of DMDs, there were studies in which no subjects used them and others in which all individuals used them. Data about the prevalence of unemployment and early retirement were available from 151 (99.3%) and 66 (43.5%) studies published from 1981 to 2021, respectively. From the results of the quality assessment, 59 (38.3%) studies were classified as high quality. The minimum data set underlying the results is reported in the S2 Table.

The pooled overall effect size for unemployment was 35.6% (95% CI 32.8–38.4; $I^2 = 99.31$). Seven (4.6%) studies resulted in effect sizes greater than 70.0%, with 5 (71.4%) published more than a decade ago [28–34]. Four (2.6%) studies registered effect sizes smaller than 5.0%, of which three were published between 2016 and 2019 [35–38]. Estimates of the prevalence of unemployment ranged from 1.4% to 80.0% (median: 41.1%). The result of the Trim and Fill
analysis \((p < 0.001)\), Egger’s linear regression test \((p < 0.004)\), and the visual inspection of the funnel plot (S1 Fig) confirmed the possibility of publication bias.

The prevalence of unemployment varied according to the year of publication \((p < 0.001)\) and there was a statistically significant decrease in the prevalence of unemployment over time \((p = 0.042)\) (Table 1, Fig 2). Globally, the proportion of unemployed subjects with MS remained relatively stable from 1981 to 2010, after which it decreased. The use of DMDs was associated with a reduced prevalence of unemployment \((p = 0.021)\) (Fig 3), especially among those with a longer disease duration \((p = 0.035)\). The decrease in unemployment prevalence over the years was more pronounced among younger individuals and those with a higher EDSS \((p = 0.024\) and \(p = 0.010\), respectively).

Data concerning the prevalence of unemployment among workers with MS were reported from 29 countries. Austria [39], Czech Republic [40], Greece [41], Hungary [42], Kuwait [43], Portugal [44], Russia [45], and Argentina [46] each contributed with one \(0.6\%\) publication reporting the prevalence of unemployed subjects. Ireland [47, 48], Israel [49, 50], Poland [51, 52], and Saudi Arabia [53, 54] contributed with two \(1.3\%\) studies each while Brazil [55–57], Iran [58–60], Holland [61–63], Norway [11, 64, 65], and Switzerland [66–68] contributed with

### Table 1. Effect sizes of prevalence of unemployment by year.

| Year | Effect size | 95% CI  | Sample size |
|------|-------------|---------|-------------|
| 1981 | 0.44        | 0.32–0.57 | 454         |
| 1982 | 0.42        | 0.35–0.49 | 198         |
| 1985 | 0.74        | 0.69–0.79 | 312         |
| 1986 | 0.79        | 0.77–0.82 | 494         |
| 1987 | 0.12        | 0.09–0.15 | 439         |
| 1989 | 0.21        | 0.18–0.25 | 508         |
| 1991 | 0.50        | 0.46–0.54 | 551         |
| 1992 | 0.18        | 0.00–0.86 | 805         |
| 1996 | 0.20        | 0.14–0.28 | 532         |
| 1997 | 0.09        | 0.07–0.12 | 697         |
| 2001 | 0.51        | 0.39–0.62 | 3884        |
| 2003 | 0.46        | 0.07–0.91 | 945         |
| 2004 | 0.58        | 0.54–0.62 | 2149        |
| 2005 | 0.59        | 0.55–0.62 | 739         |
| 2006 | 0.52        | 0.43–0.61 | 16816       |
| 2007 | 0.33        | 0.10–0.67 | 1920        |
| 2008 | 0.49        | 0.33–0.64 | 17455       |
| 2009 | 0.23        | 0.08–0.48 | 1101        |
| 2010 | 0.42        | 0.13–0.77 | 11595       |
| 2011 | 0.27        | 0.11–0.50 | 2773        |
| 2012 | 0.28        | 0.16–0.45 | 12813       |
| 2013 | 0.34        | 0.29–0.41 | 12816       |
| 2014 | 0.29        | 0.21–0.39 | 14090       |
| 2015 | 0.46        | 0.29–0.64 | 14922       |
| 2016 | 0.23        | 0.13–0.37 | 4031        |
| 2017 | 0.37        | 0.29–0.45 | 27069       |
| 2018 | 0.28        | 0.19–0.38 | 5823        |
| 2019 | 0.27        | 0.19–0.37 | 15565       |
| 2020 | 0.28        | 0.17–0.41 | 7960        |
| 2021 | 0.41        | 0.30–0.52 | 5136        |

https://doi.org/10.1371/journal.pone.0272156.t001
three (2.0%) studies each. Most of the data on the estimates of the prevalence comes from Canada (four, 2.6%) [69–72], Denmark (five, 3.3%) [73–77], Belgium (five, 3.3%) [35, 78–81], France (five, 3.3%) [82–86], Spain (five, 3.3%) [8, 28, 33, 87, 88], Sweden (seven, 4.6%) [89–95], Germany (eight, 5.3%) [96–103], Australia (eight, 5.9%) [38, 104–110], Italy (nine, 5.9%) [111–119], United Kingdom (nine, 5.9%) [29, 32, 120–126] and the United States of America (50, 32.9%) [14, 15, 30, 31, 34, 36, 37, 127–169]. Five (3.3%) studies were conducted in more than one nation [170–173]. Ireland (8.2%; 95% CI 4.2–15.3) [47, 48], Greece (9.8%; 95% CI 6.5–14.7) [40] and Argentina (15.5%; 95% CI 12.4–19.2) [45, 46] had the best estimates of effect size while Holland (62.8%; 95% CI 60.6–65.0) [61–63], Austria (59.6%; 95% CI 56.5–62.5) [39] and Portugal (46.6%; 95% CI 42.3–51.1) [44] accounted for the highest values. There was a statistically significant difference between the effect sizes of countries (p < 0.001) (Fig 4).

From the perspective of continents, 73 (48.0%) studies were performed in Europe, 54 (35.5%) in North America, eight (5.2%) in Asia, eight (5.2%) in Oceania, four (2.6%) in South America and three (2.0%) in Europe and North America. The effect sizes varied in a statistically significant way according to continents (p = 0.04), being North America the continent with the highest pooled prevalence estimate (39.1%; 95% CI 35.1–43.3). Data were provided mostly from high-income countries (142, 93.4%). Upper-middle economy countries and lower-middle economy countries accounted for six (3.9%) and three (2.0%) studies, respectively. The estimates of the prevalence of unemployment significantly varied according to the economic criteria (p = 0.04), being the highest estimate found in high-income economy countries (36.2%;
95% CI 33.3–39.1). Among countries with a high prevalence of MS, a higher educational level was associated with higher proportions of unemployed MS subjects (p = 0.024). In parallel, psychiatric disorders were associated with greater effect sizes of the prevalence of unemployment in Europe (p = 0.046). There was no statistical difference between countries classified according to the prevalence of MS.

The pooled overall effect size for early retirement was 17.2% (95% CI 14.6–20.2; I² = 99.13). In three (4.5%) studies from 2006, 2018, and 2021, the prevalence of early retirement was over 50% [74, 122, 174]. In the most recent studies, the subjects’ sample largely comprised patients who attended rehabilitation clinics or were of advanced age. Five (7.5%) studies accounted for the lowest estimates of early retirement. All were published in 2017 and were conducted in Europe [63, 66, 86, 97, 120]. There was a significant publication bias demonstrated in the funnel plot (S2 Fig), the Trim and Fill analysis (p < 0.001), and the Egger’s linear regression test (p < 0.004).

More than half of the studies included (34, 50.7%) were published in the last seven years (Table 2). Estimates of the prevalence of early retirement ranged from 1.7% to 64.0% (median: 19.2%). Only seven (31.8%) estimates obtained from studies that were published before 2010 were below the overall effect size in comparison to 27 (60.0%) estimates extracted from data published between 2010 and 2021 (p = 0.039). Nevertheless, there was no significant difference between the estimates of the prevalence of early retirement over time on meta-regression analysis (p = 0.082) (S3 Fig), except for the subgroup of younger subjects (p = 0.010) and higher
EDSS (p < 0.001). High EDSS and progressive MS phenotype were covariates directly associated with early retirement among younger individuals (p = 0.005 and p = 0.017, respectively). Among those with longer disease duration, the EDSS was a covariate associated with early retirement while among those with higher EDSS, the presence of psychiatric symptoms was the strongest determinant to the observed effect size (p = 0.007).

The studies that described the early retirement prevalence were performed in 25 countries: The United States of America (19, 28.3%) [14, 31, 36, 37, 129–132, 136, 140, 143–146, 150, 151, 160, 167, 168] Germany (five, 7.5%) [97, 99, 100, 102, 103] United Kingdom (five, 7.5%) [29,
Denmark (four, 6.0%) [73–76], Australia (three, 4.5%) [108, 109, 175], Belgium (three, 4.5%) [35, 79, 80], Holland (three, 4.5%) [61, 63, 176], Italy (three, 4.5%) [111 – 113], Ireland (two, 3.0%) [47, 48], Spain (two, 3.0%) [8, 28], Sweden (two, 3.0%) [90, 91], Switzerland (two, 3.0%) [66, 67], Argentina (one, 1.5%) [46], Austria (one, 1.5%) [39], Brazil (one, 1.5%) [55], the Czech Republic (one, 1.5%) [40], France (one, 1.5%) [86], Greece (one, 1.5%) [41], Hungary (one, 1.5%) [42], Iran (one, 1.5%) [59], Israel (one, 1.5%) [49], Russia (one, 1.5%) [45], Norway (one, 1.5%) [65], and Portugal (one, 1.5%) [44]. One (1.5%) study was multinational [170]. The overall pooled estimate of the prevalence of early retirement was 17.2% (CI 95% 14.6–20.2, $I^2 = 99.13$). The three countries with the highest effect sizes were the Czech Republic (48.9%; 95% CI 45.7–52.2) [40], Austria (44.4%; 95% CI 41.4–47.5) [39] and Brazil (37.1%; 95% CI 30.9–43.9) [56] while Russia (1.5%; 95% CI 0.4–4.5) [45], France (3.2%; 95% CI 1.9–5.5) [86] and Iran (3.7%; 95% CI 2.0–6.5) [59] had the lowest proportions (Fig 5).

The geographical distribution of the studies is uneven, with Europe (39, 58.2%) and North America (18, 26.9%) accounting for most of the publications. Asia, Oceania, and South America were responsible for three (4.5%) studies each. One study (1.5%) involved both the American and European continents. We couldn’t find any study from Africa. When classifying the countries based on the income criteria, the studies were performed in 62 (92.5%) high-income countries, four (6.0%) upper-middle-income country and only one (1.5%) in a lower-middle-income country. Comparing the effects sizes based on the geographic criteria, there was a substantial difference between countries (p < 0.001) and income-based classified countries (p < 0.001), but no statistically significant difference was found among continents (p < 0.478). We didn’t find any statistical difference between countries classified according to the prevalence of MS but psychiatric disorders were associated with higher estimates of the prevalence of early retirement in countries with high MS prevalence (p = 0.022).

Motor symptoms, gender, cognitive impairment, and fatigue were not associated with any of the outcomes. The sensitivity analysis demonstrated the robustness of our results. Excluding

### Table 2. Effect sizes of early retirement by year.

| Year | Effect size | 95% CI       | Sample size |
|------|-------------|--------------|-------------|
| 1981 | 0.14        | 0.01–0.72    | 454         |
| 1989 | 0.15        | 0.12–0.18    | 508         |
| 1991 | 0.13        | 0.10–0.16    | 551         |
| 1992 | 0.20        | 0.11–0.34    | 814         |
| 2001 | 0.33        | 0.32–0.35    | 2793        |
| 2006 | 0.37        | 0.34–0.41    | 16650       |
| 2008 | 0.04        | 0.03–0.41    | 1942        |
| 2009 | 0.15        | 0.05–0.34    | 851         |
| 2010 | 0.29        | 0.28–0.31    | 2538        |
| 2012 | 0.30        | 0.09–0.65    | 11973       |
| 2013 | 0.21        | 0.06–0.52    | 9200        |
| 2014 | 0.15        | 0.07–0.29    | 3550        |
| 2015 | 0.07        | 0.06–0.08    | 4816        |
| 2016 | 0.19        | 0.09–0.34    | 2169        |
| 2017 | 0.06        | 0.03–0.11    | 13786       |
| 2018 | 0.17        | 0.09–0.29    | 2036        |
| 2019 | 0.12        | 0.07–0.18    | 5725        |
| 2020 | 0.13        | 0.05–0.28    | 1574        |
| 2021 | 0.63        | 0.58–0.68    | 417         |

PLOS ONE | https://doi.org/10.1371/journal.pone.0272156.t002
low-quality studies and outliers detected in the funnel plot didn’t show different results for both outcomes.

Discussion

To the best of our knowledge, this is the first systematic review with a meta-analysis describing the prevalence of unemployment and early retirement in the population of PwMS. The findings confirm the significant negative impact of MS on the occupational environment and the consequently elevated proportions of individuals unemployed and early retired. According to the World Bank Data, between 1991 and 2021, the worldwide unemployment rate ranged from 4.80–6.47%, indicating that workers with MS exceed up to five times the global average estimate [177]. The high prevalence of MS in the world, the manifestation of symptoms at working age, and the presence of several potentially disabling symptoms justify these findings and the particularity of MS at the public health level [66, 178]. These eloquent numbers also give an idea about the effectiveness of the set of actions implemented at the individual and
collective level until now, since unemployment and early retirement can be considered sentinels of a spectrum of MS-related outcomes. The diversity of symptoms leaves PwMS vulnerable to a wide variety of barriers at work. In this context, screening PwMS for working difficulties may also prevent or at least postpone unfavourable occupational outcomes. Some questionnaires have already been designed and validated as potential predictors of occupational status change [86]. Moreover, an active investigation of the quality of the integration between worker and work by neurologists and occupational physicians may favour the early recognition of the difficulties and demands of PwMS in the workplace.

We found that there was a decrease in the proportion of workers with MS unemployed over time. This finding has been observed mainly in the last ten years, a period when there was a significant increase in the availability of new DMDs [179]. Indeed, we observed that the use of DMDs was associated with a decrease in the prevalence of unemployment over the years, which is in line with some preliminary evidence [3]. The possibility to control the disease and slow down its progression naturally affects the working capacity of the patient with MS [180]. Consistent with these results, we also found that the association was particularly significant in populations with a high mean EDSS and longer disease duration, important risk factors that are well known to be associated with worse occupational outcomes and that are thought to be extremely influenced by the clinical efficacy of the new MS drugs [13, 118, 151]. The decrease in the prevalence of unemployment was also particularly important among young workers, possibly due to their greater capacity to readjust and engage in new forms of work [174]. Even so, it should be mentioned that the overall observed drop was discrete and can be interpreted as disproportionate to the therapeutic advances in MS and to the time elapsed since the first study reporting the prevalence of unemployment was published. Possible explanations for this lie in the lack of efficient and validated public strategies to promote job retention in workers with MS and the lack of involvement of the occupational physician in this process. Forty percent of patients did not even communicate the diagnosis of MS to their occupational physician [181]. Many of the reasons for work withdrawal are associated with the workplace and could be potentially managed by occupational health multidisciplinary teams [44, 84, 162]. In addition, there is a lack of evidence addressing the reintegration of the worker with MS into the workforce so that nowadays unemployment usually means an irreversible outcome [181], even though almost one-third feel they are still able to work [84]. Regarding specifically early retirement, the results also reinforce the role of MS therapeutic improvement over the years [162]. In addition, aggressive disease characteristics were associated with worse effect estimates of early retirement, which is also consistent with the findings of previous results [182, 183].

We were able include a large number of countries in our analysis. There was a remarkable diversity of estimates of the prevalence of unemployment and early retirement according to the geographical classification. The wide diversity of illness-related unemployment and early retirement across different countries, even from the same continent, is supported by the pre-existing literature for other chronic diseases [184, 185] and supports the argument that occupational outcomes of PwMS are far from depending exclusively on their individual characteristics and are also directly influenced by the public health context. Several national characteristics may explain the differences between the results, so that, based on the global analysis, future studies should be dedicated to better understanding the approach of MS from the occupational viewpoint that justifies the effect sizes of each country. The accurate interpretation of every single result must consider the complexity and particularity of each country’s socio-economic characteristics. A lower unemployment rate at a national level may be associated with larger effects of poor health on not entering employment [162]. Moreover, countries with a high prevalence of unemployment in the general population may also influence the outcomes of PwMS. A general high level of education or a country where there is high competitiveness
for highly qualified jobs can explain why some estimates of the prevalence of unemployment are high in North America or high-income economy countries. Psychiatric illness may be the most influential clinical manifestation of MS responsible for patients leaving the workforce in countries and continents with a high MS prevalence. It has already been demonstrated that psychiatric illnesses play an important role in the exit of paid employment in Europe [186, 187]. Our study provides preliminary evidence concerning the observation that a higher educational level is associated with greater estimates of the prevalence of unemployment among countries with a high MS prevalence. This finding must be interpreted with caution since factors related to the country’s social, economic and cultural context can have influenced it.

The analyses were made on a large number of subjects from many countries, which strengthens the representativeness of our sample and the quality of the evidence found. We also adopted strict inclusion and exclusion criteria that resulted in a significant proportion of studies with low potential for methodological bias. Besides, our analysis did not include a large number of articles with a high risk of methodological bias. To our knowledge, not only is it the first systematic review with meta-analysis dedicated to analyzing the prevalence of unemployment and early retirement in PwMS, but it is also the first systematic review with meta-analysis to analyze these outcomes in a non-communicable neurological disorder. Our study has also some limitations that need to be acknowledged to allow an accurate interpretation of the results. Although they are relatively simple variables to be measured, by aggregating different types of studies, we could not standardize the way the studies addressed the outcomes, which may be responsible for some kind of methodological bias and the significant heterogeneity. As most of the studies had a cross-sectional design, it is not possible to draw definitive causal relations between the occupational outcomes and MS. We have seen an imbalance in the availability of literature between countries and, therefore, our results might not be representative for some countries or regions. Even though, our study provides a reasonable estimate for countries included in this review, in particular high-income countries. Our study did not include other covariates that could be related to the outcomes. However, our decision was based on which variables were more reported in all studies, preventing the inclusion of insufficient data and the generation of non-significant and unrepresentative data. Finally, we didn’t calculate a score of agreement between the researchers that were responsible for the screening and the selection of articles.

Conclusions

This systematic review shows that unemployment and early retirement due to MS remain highly prevalent, despite a slight decline in the last decade. This study adds precision and accuracy to the prevalence of unemployment and early retirement in PwMS reported by many previous studies performed in many different countries. Prospective and multicentre cohort studies are encouraged to deepen the knowledge in this field, especially in under-represented countries. The findings should spur more effective public health strategies capable of encompassing the occupational context in which PwMS are inserted to promote their occupational outcomes. Collaboration among clinicians, neurologists, occupational physicians, employers, researchers, and policymakers is urgently required to prevent and mitigate unemployment and early retirement among PwMS.

Supporting information

S1 File. PRISMA checklist.

(DOCX)
S1 Table. Detailed search strategy in PubMed, Scopus, SciVerse Science Direct and Web of Science. (DOCX)

S2 Table. Minimal data set underlying the results and full description of the articles included in the review. NA = Not Applicable. “The JBI Critical Appraisal Checklist for Studies Reporting Prevalence Data was used for the risk of bias assessment, with more stars equalling lower risk. (DOCX)

S1 Fig. Funnel plot of studies included in the analysis (unemployment). (DOCX)

S2 Fig. Funnel plot of studies included in the analysis (early retirement). (DOCX)

S3 Fig. Meta-regression (random-effects model) of the prevalence of early retirement according to time. (DOCX)

Author Contributions

Conceptualization: Bruno Kusznir Vitturi, Alborz Rahmani, Guglielmo Dini, Paolo Durando.

Data curation: Bruno Kusznir Vitturi, Alborz Rahmani, Alfredo Montecucco.

Formal analysis: Bruno Kusznir Vitturi, Alborz Rahmani.

Funding acquisition: Matilde Inglese, Paolo Durando.

Investigation: Bruno Kusznir Vitturi, Alborz Rahmani, Guglielmo Dini, Alfredo Montecucco.

Methodology: Bruno Kusznir Vitturi, Alborz Rahmani, Guglielmo Dini, Alfredo Montecucco.

Project administration: Bruno Kusznir Vitturi, Paolo Durando.

Resources: Nicoletta Debarbieri, Paolo Bandiera, Mario Alberto Battaglia, Tommaso Manecorda, Benedetta Persechino, Giuliana Buresti.

Supervision: Paolo Durando.

Writing – original draft: Bruno Kusznir Vitturi.

Writing – review & editing: Bruno Kusznir Vitturi, Alborz Rahmani, Guglielmo Dini, Michela Ponzio, Matilde Inglese, Paolo Durando.

References

1. Filippi M, Bar-Or A, Piehl F, et al. Multiple sclerosis. Nat Rev Dis Prim. 2018; 4. https://doi.org/10.1038/s41572-018-0041-4 PMID: 30410033

2. Leray E, Moreau T, Fromont A, Edan G. Epidemiology of multiple sclerosis. Rev Neurol (Paris). 2016; 172(1):3–13. https://doi.org/10.1016/j.neurol.2015.10.006 PMID: 26718593

3. Dobson R, Giovannoni G. Multiple sclerosis—a review. Eur J Neurol. 2019; 26(1):27–40. https://doi.org/10.1111/ene.13819 PMID: 30300457

4. Rumrill PD, Roessler RT, Li J, Daly K, Leslie M. The employment concerns of Americans with multiple sclerosis: Perspectives from a national sample. Work. 2015; 52(4):735–748. https://doi.org/10.3233/WOR-152201 PMID: 26599671

5. Lorefice L, Fenu G, Frau J, Coghe G, Marrosu MG, Cocco E. The impact of visible and invisible symptoms on employment status, work and social functioning in Multiple Sclerosis. Work. 2018; 60(2):263–270. https://doi.org/10.3233/WOR-182682 PMID: 29400690
6. Forslin M, Fink K, Hammar U, von Koch L, Johansson S. Predictors for Employment Status in People With Multiple Sclerosis: A 10-Year Longitudinal Observational Study. Arch Phys Med Rehabil. 2018; 99(8):1483–1490. https://doi.org/10.1016/j.apmr.2017.12.028 PMID: 29407519

7. Li J, Roessler RT, Rumrill PD Jr., Ahmed ER. Factors Influencing Job Satisfaction for Employed Adults With Multiple Sclerosis. Rehabil Couns Bull. 2017; 61(1):28–40. https://doi.org/10.1177/0034355216626216

8. Maurino J, Martínez-Ginés ML, García-Dominguez JM, et al. Workplace difficulties, health-related quality of life, and perception of stigma from the perspective of patients with Multiple Sclerosis. Mult Scier Relat Disord. 2020; 41:102046. https://doi.org/10.1016/j.msard.2020.102046 PMID: 32179482

9. Abbas D, Gehanno J-F, Caillard J-F, Beuret-Blanquart F. [Characteristics of patients suffering from multiple sclerosis according to professional situation]. Ann Readapt Med Phys Rev Sci Soc Fr Reedu Fonet Readapt Med Phys. 2008; 51(5):386–393. https://doi.org/10.1016/j.annrmp.2008.03.004 PMID: 18565608

10. Carrieri L, Sgaramella TM, Bortolon F, et al. Determinants of on-the-job-barriers in employed persons with multiple sclerosis: the role of disability severity and cognitive indices. Work. 2014; 47(4):509–520. https://doi.org/10.3233/WOR-131623 PMID: 23531588

11. Bøe Lunde HM, Telstad W, Grytten N, et al. Employment among Patients with Multiple Sclerosis-A Population Study. PLoS One. 2014; 9(7):e103317. https://doi.org/10.1371/journal.pone.0103317 PMID: 25054972

12. Conradsson DM, Forslin M, Fink K, Johansson U, von Koch L, Johansson S. Employment status of people with multiple sclerosis in relation to 10-year changes in functioning and perceived impact of the disease. Mult Scier Relat Disord. 2020; 46:102519. https://doi.org/10.1016/j.msard.2020.102519 PMID: 32977076

13. Krause I, Kern S, Horntich A, Ziemssen T. Employment status in multiple sclerosis: impact of disease-specific and non-disease-specific factors. Mult Scier. 2013; 19(13):1792–1799. https://doi.org/10.1177/1352458513485655 PMID: 23633190

14. Julian LJ, Veilla L, Vollmer T, Hadjimichael O, Mohr DC. Employment in multiple sclerosis. Exiting and re-entering the work force. J Neurol. 2008; 255(9):1354–1360. https://doi.org/10.1007/s00415-008-0910-y PMID: 18677639

15. Pack TG, Szirony GM, Kushner JD, Bellaw JR. Quality of life and employment in persons with multiple sclerosis. Work. 2014; 49(2):281–287. https://doi.org/10.3233/WOR-131711 PMID: 2404768

16. Neusser S, Biemann J, Lux G, Wasem J, Reissner V, Neumann A. Economic burden of multiple sclerosis to the social insurance system in Germany. J Public Heal. 2018; 26(3):271–278. https://doi.org/10.1007/s10389-017-0871-7

17. Battaglia M, Kobelt G, Ponzio M, Berg J, Capsa D, Dalén J. New insights into the burden and costs of multiple sclerosis in Europe: Results for Italy. Mult Scier J. 2017; 23:104–116. https://doi.org/10.1177/1352458517708176 PMID: 28643600

18. Murley C, Tinghög P, Karampampa K, Hillert J, Alexanderson K, Friberg E. Types of working-life sequences among people recently diagnosed with multiple sclerosis in Sweden: a nationwide register-based cohort study. BMJ Open. 2020; 10(12). https://doi.org/10.1136/bmjopen-2020-039228 PMID: 33376161

19. Bergamaschi R, Montomoli C, Candeloro E, et al. Bayesian mapping of multiple sclerosis prevalence in the province of Pavia, northern Italy. J Neurol Sci. 2006; 244(1):127–131. https://doi.org/10.1016/j.jns.2006.01.013 PMID: 16527310

20. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. https://doi.org/10.1136/bmj.n71 PMID: 33782057

21. Munn Z, Moolla S, Lisy K, Ritalin D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. Int J Evid Based Healthc. 2015; 13(3):147–153. https://doi.org/10.1097/XEB.0000000000000054 PMID: 26317388

22. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21 (11):1539–1558. https://doi.org/10.1002/sim.1186 PMID: 12111919
26. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629–634. https://doi.org/10.1136/bmj.315.7109.629 PMID: 9310563

27. Duval S, Tweedie R. Trim and Fill: A Simple Funnel-Plot-Based Method of Testing and Adjusting for Publication Bias in Meta-Analysis. Biometrics. 2000; 56(2):455–463. https://doi.org/10.1111/j.0006-341x.2000.00455.x PMID: 10877304

28. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Spain. Eur J Heal Econ HEPAC Heal Econ Prev Care. 2006; 7 Suppl 2:S65–74. https://doi.org/10.1007/s10188-006-0381-y PMID: 17310340

29. Kobelt G, Berg J, Lindgren P, Kerrigan J, Nixon R. Costs and quality of life of multiple sclerosis in the United Kingdom. Eur J Heal Econ HEPAC Heal Econ Prev Care. 2006; 7 Suppl 2:S96–104. https://doi.org/10.1007/s10198-006-0380-z PMID: 17310341

30. Chiu CY, Tansey TN, Chan F, Strauser D, Frain MP, Arora S. Effect of Rehabilitation Technology Services on Vocational Rehabilitation Outcomes of Individuals With Multiple Sclerosis. Rehabil Res POLICY Educ. 2015; 29(2):183–192. https://doi.org/10.1891/2168-6653.29.2.183

31. Larocca N, Kalb R, Scheinberg L, Kendall P. Factors associated with unemployment of patients with multiple sclerosis. J Chronic Dis. 1985; 38(2):203–210. https://doi.org/10.1016/0021-9681(85)90093-1 PMID: 3156140

32. Riazi A, Hobart JC, Fitzpatrick R, Freeman JA, Thompson AJ. Socio-demographic variables are limited predictors of health status in multiple sclerosis. J Neurol. 2003; 250(9):1088–1093. https://doi.org/10.1007/s00415-003-0160-y PMID: 14504971

33. Garcia-Dominguez JM, Maurino J, Martinez-Gines ML, et al. Economic burden of multiple sclerosis in a population with low physical disability. BMC Public Health. 2019; 19. https://doi.org/10.1186/s12889-019-6907-x PMID: 31103917

34. Kornbliht AB, La Rocca NG, Baum HM. Employment in individuals with multiple sclerosis. Int J Rehabil Res Int Zeitsschrift fur Rehabilitation Rev Int Rech Readapt. 1986; 9(2):155–165. https://doi.org/10.1079/0004356-198606000-00005 PMID: 3771036

35. D’hooghe MB, Haentjens P, Van Remoortel A, De Keyser J, Nagels G. Self-reported levels of education and disability progression in multiple sclerosis. Acta Neurol Scand. 2016; 134(6):414–419. https://doi.org/10.1111/ane.12555 PMID: 27761897

36. Catanzaro M, Weinert C. Economic status of families living with multiple sclerosis. Int J Rehabil Res Int Zeitsschrift fur Rehabilitation Rev Int Rech Readapt. 1992; 15(3):209–218. https://doi.org/10.1079/0004356-199209000-00004 PMID: 1428386

37. Chiu C, Park M, Hoffman T, Campbell M, Bishop M. Descriptive analysis of free-text comments on healthcare priorities and experiences in a national sample of people with multiple sclerosis. Mult Scler Relat Disord. 2019; 34:141–149. https://doi.org/10.1016/j.msard.2019.06.023 PMID: 31277032

38. Chen J, Taylor B, Palmer AJ, et al. Estimating MS-related work productivity loss and factors associated with work productivity loss in a representative Australian sample of people with multiple sclerosis. Mult Scler. 2019; 25(7):994–1004. https://doi.org/10.1177/1352458518781971 PMID: 29911469

39. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Austria. Eur J Heal Econ HEPAC Heal Econ Prev Care. 2006; 7 Suppl 2:S14–23. https://doi.org/10.1007/s10198-006-0382-x PMID: 17310339

40. Blahova Dusankova J, Kalincik T, Dolezal T, Kobelt G, Havrdova E. Cost of multiple sclerosis in the Czech Republic: the COMS study. Mult Scler. 2012; 18(5):662–668. https://doi.org/10.1177/1352458511424422 PMID: 21965424

41. Hadjigeorgiou G, Dardiotis E, Tsivgoulis G, et al. Observational study assessing demographic, economic and clinical factors associated with access and utilization of health care services of patients with multiple sclerosis under treatment with interferon beta-1b (EXTAVIA). PLoS One. 2014; 9(11): e11393. https://doi.org/10.1371/journal.pone.011393 PMID: 25419842

42. Pénéték M, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: Results for Hungary. Mult Scler. 2017; 23(2_suppl):91–103. https://doi.org/10.1177/1352458517708142 PMID: 28643591

43. Al Khader H, Emran B, Al Sulaimi M, et al. Estimating the prevalence of cognition and mental health among multiple sclerosis patients: A population-based cross-sectional study. Mult Scler Relat Disord. 2019; 36:101391. https://doi.org/10.1016/j.msard.2019.101391 PMID: 31557677

44. Sa MJ, Kobelt G, Berg J, Capsa D, Dalen J. European Multiple Sclerosis Platform. New insights into the burden and costs of multiple sclerosis in Europe: Results for Portugal. Mult Scler J. 2017; 23:143–154. https://doi.org/10.1177/1352458517708667 PMID: 28643585
45. Boyko A, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: Results for Russia. *Mult Scler*. 2017; 23(2_suppl):155–165. https://doi.org/10.1177/1352458517708668 PMID: 2643590

46. Carnero Contentti E, Pettininchi JP, López PA, et al. Access and unmet needs to multiple sclerosis care in a cohort of Argentinean patients. *Mult Scler Relat Disord*. 2019; 33:88–93. https://doi.org/10.1016/j.msard.2019.05.024 PMID: 31174044

47. Carney P, O’Boyle D, Larkin A, McGuigan C, O’Rourke K. Societal costs of multiple sclerosis in Ireland. *J Med Econ*. 2018; 21(5):425–437. https://doi.org/10.1080/13696998.2018.1427100 PMID: 29320900

48. Fogarty E, Walsh C, McGuigan C, Tubridy N, Barry M. Direct and indirect economic consequences of multiple sclerosis in Ireland. *Appil Health Econ Health Policy*. 2014; 12(6):635–645. https://doi.org/10.1007/s40258-014-0128-3 PMID: 25227118

49. Miller A, Dishon S. Health-related quality of life in multiple sclerosis: The impact of disability, gender and employment status. *Qual life Res an Int J Qual life Asp Treat care Rehabil*. 2006; 15(2):259–271. https://doi.org/10.1007/s11136-005-0891-6 PMID: 16468081

50. Rozin R, Schiff Y, Cooper G, Kahana E. Vocational rehabilitation of multiple sclerosis (MS) patients I. Analysis of clinical and demographic factors first in a series of articles. *Disabil Rehabil*. 1982; 4(2):75–79. https://doi.org/10.3109/096382828209166882 PMID: 7174216

51. Rzepeński L, Zawadka-Kunikowska M, Kucharczuk J, Newton J, Zalewski P. New insights into the clinical and demographic factors first in a series of articles. *Mult Scler*. 2017; 23(2_suppl):130–142. https://doi.org/10.1177/1352458517708666 PMID: 2643596

52. Alhussain H, Aldayel AA, Alenazi A, Alowain F. Multiple Sclerosis Patients in Saudi Arabia: Prevalence and impact of depression. *Acta Neurol Taiwan*. 2021; 20(1):205. https://doi.org/10.1186/s12913-020-1352-3 PMID: 27009599

53. Estrutti CM, Cardoso GSME, de Novais MAP, de Oliveira EML, Bichuetti DB. Employment status of people diagnosed with multiple sclerosis in Brazil: A cross-sectional multicenter study. *BMC Health Serv Res*. 2016; 16. https://doi.org/10.1186/s12913-016-1352-3 PMID: 32204649

54. Kobelt G, Teich V, Cavalcanti M, Canzonieri AM. Burden and cost of multiple sclerosis in Brazil. *PLoS One*. 2019; 14(1):e0208837. https://doi.org/10.1371/journal.pone.0208837 PMID: 30673070

55. Farnoush R, Sahel-Bolzamani M, Aliloo L, Rahmani A. Educational, psycho mental and socio economical needs of an iranian cohort with multiple sclerosis. *Oman Med J*. 2010; 25(1):22–25. https://doi.org/10.5001/omj.2010.6 PMID: 22125693

56. da Silva NL, Takemoto MLS, Damasceno A, et al. Cost analysis of multiple sclerosis in Brazil: A cross-sectional multicenter study. *BMC Health Serv Res*. 2016; 16. https://doi.org/10.1186/s12913-016-1352-3 PMID: 32204649

57. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life in multiple sclerosis in The Netherlands. *Eur J Heal Econ HEPAC Heal Econ Prev care*. 2006; 7 Suppl 2:S55–S64. https://doi.org/10.1007/s10198-006-0378-6 PMID: 17310343

58. van der Hiele K, van Gorp DAMAM, van Egmond EEEA, et al. Self-reported occupational functioning in persons with relapsing-remitting multiple sclerosis: Does personality matter? *J Neurol Sci*. 2021; 427:117561. https://doi.org/10.1016/j.jns.2021.117561 PMID: 34216973

59. AlZahran i AS, Alshamra ni FJ, Al-Khamis FA, et al. Association of acute stress with multiple sclerosis in persons with relapsing-remitting multiple sclerosis: Does personality matter? *J Neurol Sci*. 2021; 427:117561. https://doi.org/10.1016/j.jns.2021.117561 PMID: 34216973

60. Kalantari S, Karbakhsh M, Khamir Z, Kalantar Z, Sahraian MA. Perceived Social Stigma in Patients with Multiple Sclerosis: A Study from Iran. *Acta Neuroi Taiwan*. 2018; 27(1):1–8. PMID: 30315555

61. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life in multiple sclerosis in The Netherlands. *Eur J Heal Econ HEPAC Heal Econ Prev care*. 2006; 7 Suppl 2:S55–S64. https://doi.org/10.1007/s10198-006-0378-6 PMID: 17310343

62. van der Hiele K, van Gorp DAMAM, van Egmond EEEA, et al. Self-reported occupational functioning in persons with relapsing-remitting multiple sclerosis: Does personality matter? *J Neurol Sci*. 2021; 427:117561. https://doi.org/10.1016/j.jns.2021.117561 PMID: 34216973

63. Utdehaag B, Kobelt G, Berg J, Capsa D, Dalén J. New insights into the burden and costs of multiple sclerosis in Europe: Results for the Netherlands. *Mult Scler*. 2017; 23(2_suppl):117–129. https://doi.org/10.1177/1352458517708663 PMID: 2643595

64. Midgard R, Risse T, Nyland H. Impairment, disability and handicap in multiple sclerosis—A cross-sectional study in an incident cohort in Merø and Romsdal County, Norway. *J Neurol*. 1996; 243(4):337–344. https://doi.org/10.1007/BF00868408 PMID: 8965107
65. Svendsen B, Grytten N, Be L, Aarseth H, Smedal T, Myhr K-M. The economic impact of multiple sclerosis to the patients and their families in Norway. *Eur J Heal Econ* *HEPAC Heal Econ Prev care.* 2018; 19(9):1243–1257. https://doi.org/10.1007/s10198-018-0971-5 PMID: 29680926

66. Calabrèse P, Kobelt G, Berg J, Capsa D, Eriksson J. New insights into the burden and costs of multiple sclerosis in Europe: Results for Switzerland. *Mult Scler.* 2017; 23(2_suppl):192–203. https://doi.org/10.1177/1352458517708685 PMID: 28643596

67. Kobelt G, Berg J, Lindgren P, Gerfin A, Lutz J. Costs and quality of life of multiple sclerosis in Switzerland. *Eur J Heal Econ* *HEPAC Heal Econ Prev care.* 2006; 7 Suppl 2:S86–95. https://doi.org/10.1007/s10198-006-0383-9 PMID: 17310338

68. Lehmann AI, Rodgers S, Kamm CP, et al. Factors associated with employment and expected work retention among persons with multiple sclerosis: findings of a cross-sectional citizen science study. *J Neurol.* 2020; 267(10):3069–3082. https://doi.org/10.1007/s00415-020-09973-3 PMID: 32529580

69. Aronson KJ. Quality of life among persons with multiple sclerosis and their caregivers. *Neurology.* 1997; 48(1):74–80. https://doi.org/10.1212/wnl.48.1.74 PMID: 9008497

70. Hategeca C, Traboulsee AL, McMullen K, Lynd LD. Association of Unemployment and Informal Care with Stigma in Multiple Sclerosis: Evidence from the Survey on Living with Neurological Conditions in Canada. *Int J MS Care.* 2019; 21(5):214–225. https://doi.org/10.7224/1537-2073.2017-108 PMID: 31680783

71. Patten SB, Williams JVA, Lavorato DH, Berzins S, Metz LM, Bulloch AGM. Health status, stress and life satisfaction in a community population with MS. *Can J Neurol Sci.* 2012; 39(2):206–212. https://doi.org/10.1017/s03171671000324x PMID: 22343155

72. Patten SB, Williams JVA, Lavorato DH, Koch M, Metz LM. Depression as a predictor of occupational transition in a multiple sclerosis cohort. *Funcit Neurol.* 2013; 28(4):275–280. https://doi.org/10.11138/FNeur.2013.28.4.275 PMID: 24598395

73. Jennum P, Wanscher B, Frederiksen J, Kjellberg J. The socioeconomic consequences of multiple sclerosis: a controlled national study. *Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol.* 2012; 22(1):36–43. https://doi.org/10.1016/j.eunepharma.2011.05.001 PMID: 21669514

74. Johansson S, Skjerbæk AG, Ørberg KM, Boesen F, Hvid LG, Dalgaløs U. Associations between fatigue impact and lifestyle factors in people with multiple sclerosis—The Danish MS hospitals rehabilitation study. *Mult Scler Relat Disord.* 2021; 50:102799. https://doi.org/10.1016/j.msard.2021.102799 PMID: 33582566

75. Pfleger CCH, Flachs EM, Koch-Henriksen N, Hilt Pfleger CC, Meulengracht Flachs E, Koch-Henriksen N. Social consequences of multiple sclerosis (1): Early pension and temporary unemployment—a historical prospective cohort study. *Mult Scler.* 2010; 16(1):121–126. https://doi.org/10.1177/1352458509352196 PMID: 20007430

76. Rasmussen PV, Kobelt G, Berg J, Capsa D, Gannedahl M. New insights into the burden and costs of multiple sclerosis in Europe. Results for Denmark. *Mult Scler.* 2017; 23(2_suppl):53–64. https://doi.org/10.1177/1352458517708118 PMID: 29643589

77. Johansson S, Ytterberg C, Gottberg K, Holmqvist LW, von Koch L, Conradsson D. Participation in social/lifestyle activities in people with multiple sclerosis: Changes across 10 years and predictors of sustained participation. *Mult Scler.* 2020; 26(13):1775–1784. https://doi.org/10.1177/1352458519881991 PMID: 31621488

78. D’hooghe MB, De Cock A, Benedict RHB, et al. Perceived neuropsychological impairment inversely related to self-reported health and employment in multiple sclerosis. *Eur J Neurol.* 2019; 26(12):1447–1454. https://doi.org/10.1111/ene.14012 PMID: 31183915

79. Dubois B, Kobelt G, Berg J, Capsa D, Gannedahl M. New insights into the burden and costs of multiple sclerosis in Europe: Results for Belgium. *Mult Scler.* 2017; 23(2_suppl):29–40. https://doi.org/10.1177/1352458517708100 PMID: 29643598

80. Kobelt G. Costs and quality of life for patients with multiple sclerosis in Belgium. *Eur J Heal Econ* *HEPAC Heal Econ Prev care.* 2006; 7 Suppl 2:S24–33. https://doi.org/10.1007/s10198-006-0377-7 PMID: 17318662

81. Kos D, Ferdinand S, Dupontail M, et al. Assessing life balance of European people with multiple sclerosis: A multicenter clinimetric study within the RIMS network. *Mult Scler Relat Disord Rev.* 2020; 39:101879. https://doi.org/10.1016/j.msardrev.2019.101879

82. Baroin A, Chopard G, Siliman G, et al. Validation of a new quality of life scale related to multiple sclerosis and relapses. *Qual Life Res an Int J Qual life Asp Treat care Rehabil.* 2013; 22(8):1943–1954. https://doi.org/10.1007/s11136-012-0334-0 PMID: 23247892

83. Baumstark K, Pelletier J, Aghababian V, et al. Is the concept of quality of life relevant for multiple sclerosis patients with cognitive impairment? Preliminary results of a cross-sectional study. *PLoS One.* 2012; 7(1):e30627. https://doi.org/10.1371/journal.pone.0030627 PMID: 22292002
Unemployment and early retirement in people with multiple sclerosis

84. Fantoni-Quinton S, Kwiatkowski A, Vermersch P, Roux B, Hautecoeur P, Leroy A. Impact of multiple sclerosis on employment and use of job-retention strategies: The situation in France in 2015. J Rehabil Med. 2016; 48(6):535–540. https://doi.org/10.2340/16501977-2093 PMID: 27243419

85. Heinzlef O, Moliner G, van Hille B, Radoszycki L, Dourgnon P, Longin J. Economic Burden of the Out-of-Pocket Expenses for People with Multiple Sclerosis in France. Pharmacoeconomics—open. 2020; 4(4):593–603. https://doi.org/10.1016/s41669-020-00199-7 PMID: 32043229

86. Lebrun-Frenay C, Kobelt G, Berg J, Capsa D, Gannedahl M. New insights into the burden and costs of multiple sclerosis in Europe: Results for France. Mult Scier. 2017; 23(2_suppl):65–77. https://doi.org/10.1177/1352458517708125 PMID: 28643588

87. Arroyo R, Massana M, Vila C. Correlation between spasticity and quality of life in patients with multiple sclerosis: the CANDLE study. Int J Neurosci. 2013; 123(12):850–858. https://doi.org/10.3109/00207454.2013.812084 PMID: 23819835

88. Gil-González I, Pérez-San-Gregorio MA, Conrad R, Martin-Rodriguez A. Predicting improvement of quality of life and mental health over 18-months in multiple sclerosis patients. Mult Scier Relat Disord. 2021; 53:103093. https://doi.org/10.1016/j.msard.2021.103093 PMID: 34175814

89. Sundström P, Nyström L, Svenningsson A, et al. Sick leave and professional assistance for multiple sclerosis individuals in Vasterbotten County, northern Sweden. Mult Scier. 2003; 9(5):515–520. https://doi.org/10.1191/1352458503ms955oa PMID: 14582779

90. Berg J, Lindgren P, Fredrikson S, Kobelt G. Costs and quality of life of multiple sclerosis in Sweden. Eur J Heal Econ HEPAC Heal Econ Prev care. 2006; 7 Suppl 2:S75–85. https://doi.org/10.1007/s10198-006-0379-5 PMID: 17310342

91. Brundin L, Kobelt G, Berg J, Capsa D, Eriksson J. New insights into the burden and costs of multiple sclerosis in Europe: Results for Sweden. Mult Scier. 2017; 23(2_suppl):179–191. https://doi.org/10.1177/1352458517708682 PMID: 28643601

92. Flensner G, Landtblom AM, Söderhamn O, Ek AC. Work capacity and health-related quality of life among individuals with multiple sclerosis reduced by fatigue: A cross-sectional study. BMC Public Health. 2013; 13(1). https://doi.org/10.1186/1471-2458-13-224 PMID: 23497281

93. Gottberg K, Einarsson U, Ytterberg C, et al. Health-related quality of life in a population-based sample of people with multiple sclerosis in Stockholm County. Mult Scier. 2006; 12(5):605–612. https://doi.org/10.1177/1352458505070660 PMID: 17086907

94. Henriksson F, Fredriksson S, Masterman T, Jönsson B. Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden. Eur J Neuroil. 2001; 8(1):27–35. https://doi.org/10.1046/j.1468-1331.2001.00169.x PMID: 11509078

95. Murley C, Karampampa K, Alexandersson K, Hillert J, Friberg E. Diagnosis-specific sickness absence and disability pension before and after multiple sclerosis diagnosis: An 8-year nationwide longitudinal cohort study with matched references. Mult Scier Relat Disord. 2020; 42:102077. https://doi.org/10.1016/j.msard.2020.102077 PMID: 32393754

96. Becker V, Heeschven C, Schuh K, Schieb H, Ziemssen T. Patient satisfaction and healthcare services in specialized multiple sclerosis centres in Germany. Ther Adv Neurol Disord. 2018; 11:1756285617748845. https://doi.org/10.1177/1756285617748845 PMID: 29390502

97. Flachenecker P, Kobelt G, Berg J, Capsa D, Gannedahl M. New insights into the burden and costs of multiple sclerosis in Europe: Results for Germany. Mult Scier. 2017; 23(2_suppl):78–90. https://doi.org/10.1177/1352458517708141 PMID: 28643593

98. Kallmann BA, Tiel-Wilck K, Kullman JS, Engelmann U, Chan A. Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAUROS-MS observational study. Ther Adv Neurol Disord. 2019; 12:1756286419835077. https://doi.org/10.1177/1756286419835077 PMID: 30944584

99. Kobelt G, Lindgren P, Smala A, et al. Costs and quality of life in multiple sclerosis. An observational study in Germany. HEPAC Heal Econ Prev Care. 2001; 2(2):60–68. https://www.scpus.com/inward/record.jsf? iid=s-2-s-0-0034751455&partnerID=40&muid=ee6df033a358e711b37f324b5d3122e7

100. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Germany. Eur J Heal Econ HEPAC Heal Econ Prev care. 2006; 7 Suppl 2:S34–44. https://doi.org/10.1007/s10198-006-0384-6 PMID: 17310327

101. Nickel S, von dem Knesebeck O, Kofahl C. Self-assessments and determinants of HRQOL in a German MS population. Acta Neurol Scand. 2018; 137(2):174–180. https://doi.org/10.1111/ane.12854 PMID: 28975610

102. Scheinberg L, Holland N, Larocca N, Laitin P, Bennett A, Hall H. Vocational disability and rehabilitation in multiple sclerosis. Int J Rehabil Res Int Zeitschrift fur Rehabil Rev Int Rech Readapt. 1981; 4(1):61–64. https://doi.org/10.1097/00004356-198103000-00006 PMID: 7216375
Unemployment and early retirement in people with multiple sclerosis

103. Schmidt S, Jöntingmeyer P. Depression, fatigue and disability are independently associated with quality of life in patients with multiple Sclerosis: Results of a cross-sectional study. Mult Scler Relat Disord. 2019; 35:262–269. https://doi.org/10.1016/j.msard.2019.07.029 PMID: 31437741

104. Chen J, Taylor B V, Blizzard L, Simpson SJ, Palmer AJ, van der Mei IAF. Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data. J Neurol Neurosurg Psychiatry. 2018; 89(11):1200–1207. https://doi.org/10.1136/jnnp-2018-318228 PMID: 29921609

105. Chen J, Taylor B, Van der Mei I. Risk factors of leaving employment due to multiple sclerosis and changes in risk over the past decades: survival analysis with competing risks. Mult Scler J. 2019; 25 MA-P(3):348.

106. Fidao A, De Livera A, Nag N, Neate S, Jelinek GA, Simpson-Yap S. Depression mediates the relationship between fatigue and mental health-related quality of life in multiple sclerosis. Mult Scler Relat Disord. 2021;47. https://doi.org/10.1016/j.msard.2020.102620 PMID: 33247274

107. Honan CA, Brown RF, Hine DW. The multiple sclerosis work difficulties questionnaire (MSWDQ): development of a shortened scale. Disabil Rehabil. 2014; 36(8):635–641. https://doi.org/10.3109/09638288.2013.805258 PMID: 23786346

108. Kirk-Brown AK, Van Dijk PA, Simmonds RD, Bourne MP, Cooper BK. Disclosure of diagnosis of multiple sclerosis in the workplace positively affects employment status and job tenure. Mult Scler. 2014; 20(7):871–876. https://doi.org/10.1177/1352458513513967 PMID: 24263383

109. Marck CH, De Livera AM, Brown CR, et al. Health outcomes and adherence to a healthy lifestyle after a multimodal intervention in people with multiple sclerosis: Three year follow-up. PLoS One. 2018; 13 (5). https://doi.org/10.1371/journal.pone.0197759 PMID: 29791509

110. Pakenham KI. The nature of sense making in caregiving for persons with multiple sclerosis. Disabil Rehabil. 2008; 30(17):1263–1273. https://doi.org/10.1080/09636820701610320 PMID: 17896215

111. Battaglia M, Kobelt G, Ponzi J, Berg J, Capsa D, Dalén J. New insights into the burden and costs of multiple sclerosis in Europe: Results for Italy. Mult Scler. 2017; 23(2_suppl):104–116. https://doi.org/10.1177/1352458517708135 PMID: 28643600

112. Bo M, Charrion L, Bartalini S, et al. Access to social security benefits among multiple sclerosis patients in Italy: A cross-sectional study. Mult Scler Relat Disord. 2018; 24:107–112. https://doi.org/10.1016/j.msard.2018.06.016 PMID: 29982106

113. Esposito S, Sparaco M, Maniscalco GT, et al. Lifestyle and Mediterranean diet adherence in a cohort of Southern Italian patients with Multiple Sclerosis. Mult Scler Relat Disord. 2021; 47:102636. https://doi.org/10.1016/j.msard.2020.102636 PMID: 33333418

114. Kobelt G, Berg J, Lindgren P, Battaglia M, Lucioni C, Uccelli A. Costs and quality of life of multiple sclerosis in Europe: Results for Italy. Eur J Heal Econ HEPAC Heal Econ Prev care. 2006; 7 Suppl 2:S45–54. https://doi.org/10.1007/s10198-006-0385-7 PMID: 17310336

115. Patti F, Pozzilli C, Montanian E, et al. Effects of education level and employment status on HRQoL in early relapsing-remitting multiple sclerosis. Mult Scler. 2007; 13(6):783–791. https://doi.org/10.1177/13524585070073511 PMID: 17613607

116. Patti F, Russo P, Papalardo A, Macchia F, Civialleri L, Paolillo A. Predictors of quality of life among patients with multiple sclerosis: An Italian cross-sectional study. J Neurol Sci. 2007; 252(2):121–129. https://doi.org/10.1016/j.jns.2006.10.017 PMID: 17188301

117. Ponzio M, Brichetto G, Zaratini P, Battaglia MA. Workers with disability: the case of multiple sclerosis. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2015; 36(10):1835–1841. https://doi.org/10.1007/s10072-015-2265-3 PMID: 26017351

118. Ponzio M, Tacchino A, Vaccaro C, Brichetto G, Battaglia MA, Messmer Uccielli M. Disparity between perceived needs and service provision: a cross-sectional study of Italians with multiple sclerosis. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2019; 40(6):1137–1144. https://doi.org/10.1007/s10072-019-03780-2 PMID: 30810827

119. Ponzio M, Tacchino A, Vaccaro C, et al. Unmet needs influence health-related quality of life in people with multiple sclerosis. Mult Scler Relat Disord. 2020; 38:101877. https://doi.org/10.1016/j.msard.2019.101877 PMID: 31812039

120. Forbes A, While A, Mathes L, Griffiths P. Health problems and health-related quality of life in people with multiple sclerosis. Clin Rehabil. 2006; 20(1):67–78. https://doi.org/10.1177/0269215506068oa PMID: 16502752

121. Ford HL, Gery E, Johnson MH, Tennant A. Health status and quality of life of people with multiple sclerosis. Disabil Rehabil. 2001; 23(12):516–521. https://doi.org/10.1080/09636820010022090 PMID: 11432648
122. McCrone P, Heslin M, Knapp M, Bull P, Thompson A. Multiple sclerosis in the UK: service use, costs, quality of life and disability. *Pharmacoeconomics*. 2008; 26(10):847–860. https://doi.org/10.2165/00019053-200806100-00005 PMID: 18793032

123. McDonnell GV, Hawkins SA. An assessment of the spectrum of disability and handicap in multiple sclerosis: a population-based study. *Mult Scler*. 2001; 7(2):111–117. https://doi.org/10.1177/1352458500700207 PMID: 11424631

124. Mitchell JN. Multiple Sclerosis and the Prospects for Employment. *J Soc Occup Med*. 1981; 31(4):134–138. https://doi.org/10.1093/occmed/31.4.134 PMID: 6460132

125. Nicholas RS, Heaven ML, Middleton RM, et al. Personal and societal costs of multiple sclerosis in the UK: A population-based MS Registry study. *Mult Scler J—Exp Transl Clin*. 2020; 6(1):2055217320901727. https://doi.org/10.1177/2055217320901727 PMID: 32030197

126. Thompson A, Kobelt G, Berg J, Capsa D, Eriksson J, Miller D. New insights into the burden and costs of multiple sclerosis in Europe: Results for the United Kingdom. *Mult Scler*. 2017; 23(2_suppl):204–216. https://doi.org/10.1177/1352458517708687 PMID: 28643587

127. Barner AM, Cetin K, Johnson KL, Gibbons LE, Ehde DM. Validation study of prevalence and correlates of depressive symptomatology in multiple sclerosis. *Gen Hosp Psychiatry*. 2008; 30(4):311–317. https://doi.org/10.1016/j.genhosppsych.2008.04.006 PMID: 18585533

128. Beier M, Hartoonian N, D’Orio VL, et al. Relationship of perceived stress and employment status in individuals with multiple sclerosis. *Work*. 2019; 62(2):243–249. https://doi.org/10.3233/WOR-192859 PMID: 30829635

129. Bishop M, Frain MP, Rumrill PD, Rymond C. The relationship of self-management and disease modifying therapy use to employment status among adults with multiple sclerosis. *J Vocat Rehabil*. 2009; 31(2):119–127.

130. Bishop M, Frain MP, Espinosa CT, Stenhoff DM. Sources of information about multiple sclerosis: Information seeking and personal, demographic, and MS variables. *J Vocat Rehabil*. 2009; 31(2):107–117.

131. Bishop M, Roessler RT, Rumrill PD, et al. The relationship between housing accessibility variables and employment status among adults with multiple sclerosis. *J Rehabil*. 2013; 79(4):4–14. https://www.scopus.com/inward/record.uri?eid=2-s2.0-84890643468&partnerID=40&md5=067585f49328fb87acce9906198db2

132. Bishop M, Chan F, Rumrill PD, et al. Employment Among Working-Age Adults With Multiple Sclerosis: A Data-Mining Approach to Identifying Employment Interventions. *Rehabil Res POLICY Educ*. 2015; 29(2):135–152. https://doi.org/10.1891/2168-6653.29.2.135

133. Bishop M, Fraser R, Li J, et al. Life domains that are important to quality of life for people with multiple sclerosis: A population-based qualitative analysis. *J Vocat Rehabil*. 2019; 51(1):67–76. https://doi.org/10.3233/JVR-191026

134. Buchanan RJ, Radin D, Chakravorty BJ, Tyry T. Informal care giving to more disabled people with multiple sclerosis. *Disabil Rehabil*. 2009; 31(15):1244–1256. https://doi.org/10.1080/09638280802532779 PMID: 19802928

135. Buhse M, Banker WM, Clement LM. Factors associated with health-related quality of life among older people with multiple sclerosis. *Int J MS Care*. 2014; 16(1):10–19. https://doi.org/10.7224/1537-2073.2012-046 PMID: 24688350

136. Chamot E, Kister I, Cutter GR. Item response theory-based measure of global disability in multiple sclerosis derived from the Performance Scales and related items. *BMC Neurol*. 2014; 14:192. https://doi.org/10.1186/s12883-014-0192-1 PMID: 25278315

137. Chiu C-Y, Fitzgerald SD, Strand DM, Muller V, Brooks J, Chan F. Motivational and Volitional Variables Associated With Stages of Change for Exercise in Multiple Sclerosis: A Multiple Discriminant Analysis. *Rehabil Couns Bull*. 2012; 56(1):23–33. https://doi.org/10.1177/0034355212439898

138. Chwastiak LA, Gibbons LE, Ehde DM, et al. Fatigue and psychiatric illness in a large community sample of persons with multiple sclerosis. *J Psychosom Res*. 2005; 59(5):291–298. https://doi.org/10.1016/j.jpsychres.2005.06.001 PMID: 16253619

139. Clingerman E, Stuifbergen A, Becker H. The influence of resources on perceived functional limitations among women with multiple sclerosis. *J Neurosci Nurs J Am Assoc Neurosci Nurses*. 2004; 36(6):312–321. https://doi.org/10.1097/01376517-200412000-00004 PMID: 15673206

140. Cofield SS, Thomas N, Tyry T, Fox RJ, Salter A. Shared Decision Making and Autonomy Among US Participants with Multiple Sclerosis in the NARCOMS Registry. *Int J MS Care*. 2017; 19(6):303–312. https://doi.org/10.7224/1537-2073.2016-091 PMID: 29270088

141. Coleman CI, Sidovar MF, Roberts MS, Kohn C. Impact of mobility impairment on indirect costs and health-related quality of life in multiple sclerosis. *PLoS One*. 2013; 8(1):e54756. https://doi.org/10.1371/journal.pone.0054756 PMID: 23355896
142. Genevie L, Kallou JE, Streuning EL. Job Retention Among People with Multiple Sclerosis. *Neurorehabil Neural Repair.* 1987; 1(3):131–135. https://doi.org/10.1177/136104098700100304

143. Glanz BI, Dégano IR, Rintell DJ, Chitnis T, Weiner HL, Healy BC. Work productivity in relapsing-multiple sclerosis: associations with disability, depression, fatigue, anxiety, cognition, and health-related quality of life. *Value Heal Int Soc Pharmacoeconomics Outcomes Res.* 2012; 15(8):1029–1035. https://doi.org/10.1016/j.jval.2012.07.010 PMID: 23244804

144. Gross HJ, Watson C. Characteristics, burden of illness, and physical functioning of patients with relapsing-remitting and secondary progressive multiple sclerosis: a cross-sectional US survey. *Neuropsychiatr Dis Treat.* 2013; 13:1349–1357. https://doi.org/10.2147/NDDT.S132079 PMID: 28572730

145. Gulick EE, Yam M, Touw MM. Work performance by persons with multiple sclerosis: conditions that impede or enable the performance of work. *Int J Nurs Stud.* 1989; 26(4):301–311. https://doi.org/10.1016/0020-7489(89)90017-5 PMID: 2613450

146. Gulick EE. Reliability and validity of the work assessment scale for persons with multiple sclerosis. *Nurs Res.* 1991; 40(2):107–112. PMID: 2003069

147. Gulick EE. Model for predicting work performance among persons with multiple sclerosis. *Nurs Res.* 1992; 41(5):266–272. PMID: 1523107

148. Gulick EE. Health status, work impediments, and coping related to work roles of women with multiple sclerosis. *Work.* 1996; 6(3):153–166. https://doi.org/10.3233/WOR-1996-6303 PMID: 24441530

149. Iezzoni LI, Ngo L. Health, disability, and life insurance experiences of working-age persons with multiple sclerosis. *Multi Scler.* 2007; 13(4):534–546. https://doi.org/10.1177/1352458506071356 PMID: 17463076

150. Iezzoni LI, Rao SR, Kinkel RP. Experiences acquiring and using mobility aids among working-age persons with multiple sclerosis. *Value Heal Int Soc Pharmacoeconomics Outcomes Res.* 2012; 15(8):1010–1023. https://doi.org/10.1016/j.jval.2012.07.010 PMID: 20881588

151. Iwanaga K, Wu J-R, Chen X, et al. Person-environment contextual factors as mediators for the relationship between symptom cluster and employment outcome in multiple sclerosis. *J Vocat Rehabil.* 2018; 48(2):197–206. https://doi.org/10.3233/JVR-180930

152. Johnson KL, Bamer AM, Fraser RT. Disease and demographic characteristics associated with unemployment among working-age adults with multiple sclerosis. *Int J MS Care.* 2013; 15(SUPPL.1):44–51.

153. Jones E, Pike J, Marshall T, Ye X. Quantifying the relationship between increased disability and health care resource utilization, quality of life, work productivity, health care costs in patients with multiple sclerosis in the US. *BMC Health Serv Res.* 2016; 16:294. https://doi.org/10.1186/s12913-016-1532-1 PMID: 27443278

154. Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. *Neurology.* 2006; 66(11):1696–1702. https://doi.org/10.1212/01.wnl.0000218309.01322.5c PMID: 16769943

155. Koch LC, Rumrill PD Jr., Roessler RT, Fitzgerald S. Illness and demographic correlates of quality of life among people with multiple sclerosis. *Rehabil Psychol.* 2001; 46(2):154–164. https://doi.org/10.1037/0090-5550.46.2.154

156. Kohn CG, Coleman CI, White CM, Sidovar MF, Sobieraj DM. Mobility, walking and physical activity in persons with multiple sclerosis. *Curr Med Res Opin.* 2014; 30(9):1857–1862. https://doi.org/10.1185/03007995.2014.921147 PMID: 24803286

157. Krause JS, Dismuke-Greer CE, Jarnecce M, Li C, Reed KS, Rumrill P. Employment and Gainful Earnings Among Those With Multiple Sclerosis. *Arch Phys Med Rehabil.* 2019; 100(5):931–937.e1. https://doi.org/10.1016/j.apmr.2018.11.005 PMID: 30529324

158. Krause JS, Li C, Backus D, et al. Barriers and Facilitators to Employment: A Comparison of Participants With Multiple Sclerosis and Spinal Cord Injury. *Arch Phys Med Rehabil.* Published online March 2021. https://doi.org/10.1016/j.apmr.2021.02.015 PMID: 33684369

159. Li J, Fitzgerald SM, Bishop M, Rumrill PD, Wang F. Disease-related and functional predictors of employment status among adults with multiple sclerosis. *Work.* 2015; 52(4):789–797. https://doi.org/10.3233/WOR-152206 PMID: 26599675

160. Molt RW, Suh Y, Weikert M, Dlugonski D, Balantrapu S, Sandroff B. Fatigue, depression, and physical activity in relapsing-remitting multiple sclerosis: Results from a prospective, 18-month study. *Mult Scler Relat Disord.* 2012; 1(1):43–48. https://doi.org/10.1016/j.msard.2011.08.003 PMID: 25876450

161. Nery-Hurwit M, Yun J, Ebbeck V. Examining the roles of self-compassion and resilience on health-related quality of life for individuals with Multiple Sclerosis. *Disabil Health J.* 2018; 11(2):256–261. https://doi.org/10.1016/j.dhjo.2017.10.010 PMID: 29089214
162. Neuberger EE, Abbass IM, Jones E, Engmann NJ. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis. *Neurol Ther*. 2021; 10(1):183–196. https://doi.org/10.1007/s40120-020-00224-1 PMID: 3244713

163. Rataska JA, Glanzki BI, Chitnis T, Weiner HL, Healy BC. Social support in multiple sclerosis: Associations with quality of life, depression, and anxiety. *J Psychosom Res*. 2020; 138:110252. https://doi.org/10.1016/j.jpsychores.2020.110252 PMID: 32971435

164. Roessler RT, Rumrill PD, Fitzgerald SM. Predictors of Employment Status for People with Multiple Sclerosis. *Rehabil Couns Bull*. 2004; 47(2):96–103. https://doi.org/10.1177/00343552030470020401

165. Roessler RT, Rumrill PD, Li J, Daly K, Anhalt K. High-priority employment concerns of Hispanics/Latinos with multiple sclerosis in the United States. *J Vocat Rehabil*. 2016; 45(2):121–131. https://doi.org/10.3323/JVR-160817

166. Sailer AR, Cutter GR, Tyyt T, Marrie RA, Vollmer T. Impact of loss of mobility on instrumental activities of daily living and socioeconomic status in patients with MS. *Curr Med Res Opin*. 2010; 26(2):493–500. https://doi.org/10.1080/13696998.2016.1277229 PMID: 28035846

167. Stuifbergen AK, Blozis S, Becker H, Harrison T, Kullberg V. Selected health behaviors moderate the progression of functional limitations in persons with multiple sclerosis: Eleven years of annual follow-up. *Disabil Health J*. 2016; 9(3):472–478. https://doi.org/10.1016/j.dhjo.2016.01.006 PMID: 26905974

168. Bass AD, Van Wijmeersch B, Mayer L, et al. Effect of Multiple Sclerosis on Daily Activities, Emotional Well-being, and Relationships: The Global vsMS Survey. *Int J MS Care*. 2020; 22(4):158–164. https://doi.org/10.7224/1537-2073.2018-087 PMID: 32863783

169. Fernandez O, Baumstarck-Barrak K, Simeoni M-CC, et al. Patient characteristics and determinants of quality of life in an international population with multiple sclerosis: Assessment using the MusiQoL and SF-36 questionnaires. *Mult Scler J*. 2011; 17(10):1238–1249. https://doi.org/10.1177/1352458510391341 PMID: 21669936

170. Fernandez-Jimenez E, Panyavin I, Perez-San-Gregorio MA, Schultheis MT. Quality of Life and Depressive Symptomatology in Multiple Sclerosis: A Cross-Sectional Study Between the USA and Spain. *Psicothema*. 2021; 33(1):60–69. https://doi.org/10.7334/psicothema2020.151 PMID: 33453737

171. Krokavcova M, Nagyova I, van Dijk JP, et al. Mastery, functional disability and perceived health status in patients with multiple sclerosis. *Eur J Neurol*. 2008; 15(11):1237–1244. https://doi.org/10.1111/j.1468-1331.2008.02304.x PMID: 18936913

172. Pflueger A, Petrovic K, Berger T, et al. Patient-reported quality of life in multiple sclerosis differs between cultures and countries: a cross-sectional Austrian-German-Polish study. *Mult Scler*. 2011; 17(4):478–486. https://doi.org/10.1177/1352458510391341 PMID: 21148265

173. Taylor KL, Hadgkiss EJ, Jelinek GA, et al. Lifestyle factors, demographics and medications associated with depression risk in an international sample of people with multiple sclerosis. *BMC Psychiatry*. 2014; 14:327. https://doi.org/10.1186/s12888-014-0327-3 PMID: 25467385

174. Broersma F, Oeseburg B, Dijkstra J, Wynnia K. The impact of self-perceived limitations, stigma and sense of coherence on quality of life in multiple sclerosis patients: results of a cross-sectional study. *Clin Rehabil*. 2018; 32(4):536–545. https://doi.org/10.1177/0269215517730670 PMID: 28895427

175. The World Bank Data. [Cited 6 December 2021]. https://data.worldbank.org/indicator/SL.UEM.TOTL.ZS. Access on 06/12/2021.

176. Honan CA, Brown RF, Hine DW, Vowels L, Wollin JA, Simmons RD, et al. The multiple sclerosis work difficulties questionnaire. *Mult Scler*. 2012 Jun; 18(6):871–80. https://doi.org/10.1177/1352458511431724 Epub 2011 Dec 6. PMID: 22146603.

177. Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. *Mult Scler J*. 2020; 26(14):1816–1821. https://doi.org/10.1177/1352458520970841 PMID: 33174475

178. McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and Treatment of Multiple Sclerosis. *JAMA*. 2021; 325(8):765. https://doi.org/10.1001/jama.2020.26858 PMID: 33620411

179. Heinonen T, Castrén E, Luukkaala T, Mäkinen K, Ruutuinen J, Kuusisto H. The retirement rate due to multiple sclerosis has decreased since 1995—A retrospective study in a Finnish central hospital. *Mult Scler Relat Disord*. 2020; 45:102360. https://doi.org/10.1016/j.msard.2020.102360 PMID: 32688302
182. Marck CH, Altken Z, Simpson S Jr, Welland TJ, Kavanagh, Jelinek GA. Predictors of Change in Employment Status and Associations with Quality of Life: A Prospective International Study of People with Multiple Sclerosis. *Mult Scler*. 2009; 15(9):S158–S159.

183. Phillips LJ, Stuifbergen AK. Predicting continued employment in persons with multiple sclerosis. *J Rehabil*. 2006; 72(1):35–43. https://www.scopus.com/inward/record.uri?eid=2-s2.0-33645781820&partnerID=40&md5=f8d8c4463a589c3000b290d862bac925

184. Schuring M, Burdorf L, Kunst A, Mackenbach J. The effects of ill health on entering and maintaining paid employment: evidence in European countries. *J Epidemiol Community Heal*. 2007; 61(7):597–604. https://doi.org/10.1136/jech.2006.047456 PMID: 17568051

185. Schuring M, Burdorf A, Kunst A, Voorham T, Mackenbach J. Ethnic differences in unemployment and ill health. *Int Arch Occup Environ Health*. 2009; 82(8):1023–1030. https://doi.org/10.1007/s00420-009-0408-7 PMID: 19234860

186. Alavinia SM, Burdorf A. Unemployment and retirement and ill-health: a cross-sectional analysis across European countries. *Int Arch Occup Environ Health*. 2008; 82(1):39–45. https://doi.org/10.1007/s00420-008-0304-6 PMID: 18264715

187. Porru F, Burdorf A, Robroek SJW. The impact of depressive symptoms on exit from paid employment in Europe: a longitudinal study with 4 years follow-up. *Eur J Public Health*. 2019; 29(1):134–139. https://doi.org/10.1093/eurpub/cky136 PMID: 30052918